Given the roles of BCL6 along with BLIMP1 and AIM2 in B-cell differentiation [64–66], a recent study implicates this regulatory pathway as a novel target for SLE treatment [66]. The gene discussed is PRDM1; the disease is systemic lupus erythematosus.